Tumor size changes in melanoma patients (Ipilimumab-refractory melanoma (KEYNOTE -002))

	Number of Prior Line of Therapy Received
	1				2 +
	(2L)				(3L+)
	n	Median	Mean	Standard Deviation	n	Median	Mean	Standard Deviation
Pembrolizumab arm
% of Early Tumor Size Changes (~Week 12)	78	−7.4	−10.0	31.3	200	−0.1	−2.4	43.1
Best % of Tumor Size Changes	78	−11.2	−23.5	43.2	200	−9.4	−16.0	53.5